NCT05183828View on ClinicalTrials.gov

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 23, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Breast AdenocarcinomaInvasive Breast Carcinoma of No Special Type

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of saliva samples

DRUG

Letrozole

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT05183828 - Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer | Biotech Hunter | Biotech Hunter